Yes, absolutely! QuickRx Specialty Pharmacy provides completely free support to help patients enroll in Keveyis (dichlorphenamide) copay assistance programs. We never charge service fees for any of our copay assistance coordination services, and the manufacturer assistance programs themselves are specifically designed to reduce or eliminate your out-of-pocket medication costs.

What “free” means at QuickRx:

No enrollment fees: We don’t charge you to apply for manufacturer copay cards, patient assistance programs, or foundation grants. Our enrollment support is 100% complimentary.

No service fees: Unlike some specialty pharmacies, QuickRx doesn’t add service fees, administrative fees, or coordination fees to your prescription cost. You pay only what your insurance requires plus any applicable copay (which we help reduce through assistance programs).

No consultation charges: Speaking with our copay assistance specialists, getting personalized cost estimates, or receiving ongoing support throughout your treatment—all completely free.

No hidden costs: We’re transparent about all costs. If there’s a copay or cost-sharing amount after insurance and assistance programs are applied, we’ll tell you exactly what you’ll pay before filling your prescription.

How QuickRx gets compensated:

You might wonder: “If QuickRx doesn’t charge me, how do they make money?” Fair question! Here’s how specialty pharmacies like QuickRx operate:

Insurance reimbursement: QuickRx is compensated by your insurance company when we fill your Keveyis prescription, just like any pharmacy. This is part of your existing insurance coverage—no additional cost to you.

Manufacturer relationships: Pharmaceutical manufacturers sometimes provide support to specialty pharmacies that help patients access their medications. This allows us to offer enhanced services like copay assistance coordination without charging patients directly.

Volume efficiencies: By specializing in medications like Keveyis for periodic paralysis, we develop expertise and efficiencies that allow us to provide superior service without adding fees.

The bottom line: You are never our source of revenue for copay assistance services. We’re incentivized to help you access affordable treatment because that’s our business model—and because it’s the right thing to do for patients with rare conditions like periodic paralysis.

What about the copay assistance programs themselves?

Manufacturer copay cards (commercial insurance): These are provided free by the medication manufacturer to eligible patients with private insurance. There’s no cost to enroll, and the savings are applied automatically at the pharmacy.

Patient assistance programs (uninsured/low income): Free medication programs for patients who can’t afford Keveyis. No fees to apply, and if approved, you receive your medication at no cost.

Foundation grants (Medicare/Medicaid): Independent charitable foundations provide grants to help patients afford their medication costs. No application fees, and QuickRx handles all the paperwork for you.

Compare this to other options:

Some patients try to navigate copay assistance on their own or through other pharmacies and encounter:

• Complicated application processes with no guidance
• Long wait times on manufacturer hotlines
• Denials because applications weren’t completed correctly
• Delays in getting medication while figuring out assistance
• Higher costs because they didn’t know all available programs

QuickRx eliminates these frustrations by handling everything for you—at no charge.

Is there ANY situation where QuickRx charges fees?

No. Our copay assistance coordination is always free, regardless of:

• Your insurance type (commercial, Medicare, Medicaid, or uninsured)
• How complex your case is
• How many programs we need to apply to on your behalf
• Whether you qualify for assistance or not
• How long it takes to get you approved

Even if you ultimately don’t qualify for assistance programs, QuickRx never charges you for trying. And we’ll still work with you to find the most affordable way to access your Keveyis prescription.

Ready to get started?

Call QuickRx at (917) 830-2525 or toll-free at (800) 496-6111 for a free consultation about Keveyis copay assistance options for your specific situation. Or complete our online enrollment form and a specialist will contact you within one to two business days.

There’s absolutely no obligation, no cost, and no risk. Let us help you access affordable Keveyis treatment today.

Eligibility for Keveyis (dichlorphenamide) copay assistance depends primarily on your insurance coverage type and financial situation. QuickRx provides a free eligibility assessment for your specific circumstances.

Step 1: Contact QuickRx

Call us at (917) 830-2525 or toll-free at (800) 496-6111, or fill out our secure online form. A QuickRx specialist will reach out to you within one to two business days.

Step 2: Complete enrollment forms

We’ll help you fill out short forms with your insurance details and prescription information.

Step 3: Provide basic documentation

Submit simple paperwork so our team can verify your eligibility for available programs.

That’s it! From there, QuickRx handles everything—from confirming your eligibility to applying discounts directly at the pharmacy. We’ll also coordinate medication pickup or home delivery and continue monitoring your benefits so you never experience a lapse in copay assistance.

General eligibility guidelines:

Commercial insurance patients typically qualify for manufacturer copay cards if they have private insurance and a valid Keveyis or dichlorphenamide prescription for an approved medical condition.

Medicare patients cannot use manufacturer copay cards due to federal regulations.

Uninsured patients may qualify for patient assistance programs that provide free or low-cost medication based on income and financial hardship.

Getting a Keveyis copay card is straightforward when you work with QuickRx. Here’s the simple process:

Step 1: Initial Contact

Call QuickRx at (917) 830-2525, or fill out our secure online application form. You can also reach us at (800) 496-6111.

Step 2: Provide Information

Share your insurance details and prescription information with our team. We’ll need:

• Your insurance card information
• Your Keveyis or dichlorphenamide prescription from your doctor
• Basic personal information for the application

Step 3: Application Submission

QuickRx completes and submits your copay card application to the manufacturer on your behalf. We handle all the paperwork so you don’t have to worry about it.

Step 4: Approval

Most patients receive approval within 24 to 48 hours. We’ll notify you as soon as your copay card is active.

Step 5: Start Saving

Once approved, your copay savings apply automatically at the pharmacy. You’ll see the reduced price when you pick up your next Keveyis or dichlorphenamide prescription.

What happens next:

QuickRx continues monitoring your copay card status and handles any renewals needed. We’ll also coordinate your prescription refills and can arrange home delivery if you prefer.

If you’re initially denied for any reason, our team will help with the appeals process or connect you to alternative assistance programs.

Ready to apply? Contact us today for free help getting your Keveyis copay card.

Medicare patients cannot use manufacturer copay cards due to federal regulations, but you still have options for financial assistance.

Why Medicare patients can’t use copay cards:

Federal law prohibits pharmaceutical manufacturers from offering copay cards or direct financial assistance to Medicare beneficiaries. This includes Medicare Part D prescription coverage.

Ready to explore your options? Call QuickRx at (917) 830-2525 to speak with a specialist about financial assistance options for Keveyis. We’ll identify which programs you qualify for and handle all the paperwork on your behalf.

The cost of Keveyis (dichlorphenamide) varies depending on your insurance coverage and whether you use copay assistance programs.

Without insurance or assistance:

Keveyis and generic dichlorphenamide can be expensive when paying out-of-pocket. Costs vary by pharmacy and dosage prescribed.

With insurance but no copay assistance:

Your out-of-pocket costs depend on your specific insurance plan, including your deductible, formulary tier, and plan design. Some plans may require prior authorization before covering Keveyis or dichlorphenamide.

With copay assistance programs:

Commercial insurance + copay card:

Eligible patients with commercial insurance may significantly reduce their copay with the manufacturer’s copay card program. Many patients pay little to nothing out-of-pocket.

Uninsured + patient assistance program:

Patients without insurance may qualify to receive Keveyis at no cost or significantly reduced prices through manufacturer patient assistance programs.

Get a personalized cost assessment:

Call QuickRx at (917) 830-2525 for a free cost analysis with all available assistance programs applied. We’ll give you real numbers based on your specific insurance and financial situation—not vague estimates.

Keveyis is the brand name for dichlorphenamide, a prescription carbonic anhydrase inhibitor indicated for the treatment of primary periodic paralysis in adults. Both brand Keveyis and generic dichlorphenamide contain the same active ingredient and are used for treating hyperkalemic periodic paralysis, hypokalemic periodic paralysis, and related variants of this rare genetic disorder.

About periodic paralysis:

Periodic paralysis is a rare neuromuscular disorder characterized by recurrent episodes of skeletal muscle weakness or paralysis. These attacks can vary in frequency, duration, and severity, significantly impacting daily activities and quality of life.

How dichlorphenamide (Keveyis) works:

Dichlorphenamide is a carbonic anhydrase inhibitor that works by reducing the frequency and severity of paralytic episodes in patients with primary periodic paralysis. The medication helps stabilize muscle function through its effects on cellular ion channels and pH balance.

Clinical evidence:

Studies have demonstrated the efficacy and safety of dichlorphenamide for treating primary periodic paralysis, with research showing significant reduction in attack frequency and improved quality of life for patients.

Important to know:

Dichlorphenamide (Keveyis) is taken by mouth, typically twice daily. While Keveyis is not a cure for periodic paralysis, it plays an important role in managing these conditions and improving quality of life when used as part of a comprehensive treatment plan under your doctor’s supervision.

Important: This information is for educational purposes only. Always consult your neurologist or healthcare provider for medical decisions about Keveyis or generic dichlorphenamide treatment and to discuss whether this medication is appropriate for your specific condition.

Keveyis (dichlorphenamide) has FDA-approved uses for adults with primary periodic paralysis:

Primary periodic paralysis treatment:

Keveyis and generic dichlorphenamide are indicated for reducing the frequency and severity of paralytic attacks in adults diagnosed with primary periodic paralysis, including:

• Hyperkalemic periodic paralysis
• Hypokalemic periodic paralysis
• Related variants of periodic paralysis

How Keveyis provides benefit:

The medication works by helping to stabilize muscle cell function and reduce the sudden shifts that trigger paralysis attacks. By maintaining more consistent cellular ion balance, dichlorphenamide helps patients experience fewer and less severe episodes of muscle weakness.

Clinical evidence:

Clinical studies have shown Keveyis to be effective in reducing the frequency of paralytic episodes in patients with genetically diagnosed periodic paralysis. Research has demonstrated meaningful improvements in attack rates and patient quality of life over several weeks to months of treatment.

Your neurologist will determine if Keveyis is appropriate for your specific situation based on your diagnosis, attack frequency, and overall health status.

Keveyis and generic dichlorphenamide should be taken exactly as your doctor prescribes. Here are general guidelines for taking this medication safely and effectively:

Timing and administration:

Take dichlorphenamide by mouth as directed by your physician, typically twice daily.

Swallow the tablets whole with water. Don’t crush, chew, or break the tablets, as this can affect how the medication works.

If you miss a dose:

Take your missed dose as soon as you remember. Don’t double up on doses to make up for the one you missed. Just continue with your regular schedule.

Storage:

Keep Keveyis or dichlorphenamide tablets at room temperature, away from excessive heat and moisture.

Key reminders:

• Take dichlorphenamide exactly as prescribed every day, even if you feel fine
• Periodic paralysis management requires consistent, long-term treatment, and it may take time to see the full benefits
• Don’t skip doses, as this can affect how well the medication works
• Never stop taking Keveyis or change your dose without talking to your doctor first

If you have questions about how to take your medication, contact QuickRx or speak with your pharmacist.

Keveyis (dichlorphenamide) can interact with several other medications. It’s essential to tell your doctor and pharmacist about all medications you’re taking, including prescription drugs, over-the-counter medicines, and supplements.

Important drug interactions:

Amantadine: Carbonic anhydrase inhibitors like dichlorphenamide may increase serum concentrations of amantadine. Your doctor should monitor you if you take both medications.

Amphetamines: Carbonic anhydrase inhibitors may decrease excretion of amphetamines. Monitoring is recommended if taking both.

Amphotericin B: May increase hypokalemic effects of dichlorphenamide. Your doctor should monitor you for this interaction.

What you should do:

Always inform your healthcare team about everything you’re taking before starting dichlorphenamide. Your doctor or pharmacist can review your medication list and advise you on proper timing to avoid interactions. They’ll also monitor you for any signs of reduced effectiveness or side effects that might indicate an interaction is occurring.

Note: This is not a complete list of all possible drug interactions. For comprehensive interaction information specific to your medications, consult your healthcare provider or pharmacist.

Like all medications, Keveyis (dichlorphenamide) can cause side effects, though not everyone experiences them. Many patients tolerate dichlorphenamide well when taken as prescribed.

Common side effects:

The most frequently reported side effects in clinical studies include:

• Paresthesia (tingling sensations) – very common, occurring in 44% of patients
• Cognitive dysfunction (including decreased mental acuity, disturbance in attention) – 14% of patients
• Confusion – 11% of patients

Other reported side effects (1-10% of patients):

• Dizziness, fatigue, headache
• Lethargy, malaise
• Diarrhea, nausea
• Pruritus (itching), skin rash
• Weight loss
• Muscle spasm, muscle twitching, arthralgia (joint pain)
• Dyspnea (shortness of breath)
• Hypoesthesia (decreased sensation)

Most of these side effects are mild and may improve as your body adjusts to the medication.

Serious side effects—contact your doctor immediately if you experience:

Postmarketing reports (reported after FDA approval):

• Heart failure, syncope (fainting)
• Abdominal cramps, anorexia
• Pancytopenia (low blood cell counts)
• Amnesia, asthenia (weakness), ataxia (loss of coordination), hallucination, numbness, psychosis, seizure, stupor, tremor
• Flank pain, nephrolithiasis (kidney stones), renal tubular necrosis

What to do about side effects:

If you experience bothersome but not severe side effects, talk to your doctor. They may be able to adjust your dose or suggest ways to manage symptoms. Never stop taking dichlorphenamide without consulting your doctor first.

You can report side effects to the FDA at 1-800-FDA-1088.

Certain people should not take Keveyis (dichlorphenamide) due to safety concerns. Always discuss your complete medical history with your doctor before starting this medication.

Do not take Keveyis if you:

Have a sulfonamide allergy: If you’re allergic or hypersensitive to dichlorphenamide or any other ingredient in Keveyis tablets, you shouldn’t take this medication. Dichlorphenamide is a sulfonamide derivative, so patients with sulfonamide allergies may also react to this drug.

Before starting Keveyis, tell your doctor if you:

• Have any allergies or sensitivities to medications
• Are pregnant, planning to become pregnant, or breastfeeding
• Have kidney or liver problems
• Have any other medical conditions
• Take any other medications or supplements

Special considerations:

The safety and effectiveness of dichlorphenamide haven’t been established in children. Elderly patients may be more sensitive to side effects and should be monitored carefully.

Important: This information is for educational purposes only and does not replace professional medical advice. Always consult your neurologist or healthcare provider before starting or stopping Keveyis treatment.

The time it takes to see results from Keveyis (dichlorphenamide) depends on your individual condition and how your body responds to the medication.

What clinical studies show:

Clinical studies demonstrated that dichlorphenamide is effective in reducing the frequency of paralytic episodes in patients with primary periodic paralysis. Patients in these studies showed meaningful improvements over several weeks to months of treatment.

Important reminders:

• Take Keveyis or dichlorphenamide exactly as prescribed every day, even if you don’t notice any immediate changes
• Periodic paralysis management requires consistent, long-term treatment
• Don’t skip doses, as this can affect how well the medication works
• Dichlorphenamide works best as part of a complete treatment plan that may include lifestyle modifications and regular monitoring
• Never stop taking Keveyis or change your dose without talking to your doctor

Your doctor will monitor your response to treatment and may adjust your dosing based on how you’re responding. If you have concerns about your treatment progress, discuss them with your neurologist.

The safety of Keveyis (dichlorphenamide) during pregnancy and breastfeeding is not fully established, so it’s important to have a detailed discussion with your doctor.

Pregnancy:

Dichlorphenamide has not been extensively studied in pregnant women, so the potential effects on an unborn baby are not fully known. Women who can become pregnant should discuss the risks and benefits with their doctor before starting Keveyis.

If you’re currently pregnant or planning to become pregnant:

Talk to your doctor immediately. They’ll evaluate whether dichlorphenamide is appropriate for your situation or if alternative treatments would be safer.

Breastfeeding:

It’s not known whether dichlorphenamide passes into human breast milk or what effects it might have on a nursing infant.

If you’re breastfeeding, your doctor will help you decide whether to:

• Continue breastfeeding while taking Keveyis
• Stop taking dichlorphenamide while you’re nursing
• Temporarily stop breastfeeding during treatment
• Use alternative medications

Never start or stop any medication during pregnancy or while breastfeeding without medical guidance. Your neurologist and OB-GYN should work together to create the safest treatment plan for both you and your baby.

Keveyis (dichlorphenamide) is specifically FDA-approved for the treatment of primary periodic paralysis, making it a targeted therapy for this rare neuromuscular condition.

Key characteristics of dichlorphenamide:

Carbonic anhydrase inhibitor: Dichlorphenamide works by inhibiting carbonic anhydrase, which affects cellular pH and ion balance. This mechanism helps stabilize muscle cell function and reduce paralytic attacks.

FDA-approved indication: Keveyis has specific FDA approval for treating primary periodic paralysis in adults, including both hyperkalemic and hypokalemic forms of the condition.

Oral administration: Dichlorphenamide is taken by mouth, typically twice daily, making it convenient for long-term management.

Clinical evidence: Studies have demonstrated dichlorphenamide’s effectiveness in reducing attack frequency and improving quality of life for patients with genetically diagnosed periodic paralysis.

Treatment approach:

Your neurologist will determine if Keveyis is the best treatment option for your specific type of periodic paralysis based on your diagnosis, attack frequency, other medical conditions, and how you respond to therapy.

Dichlorphenamide is a substrate of OAT1/3 transporters, which affects how the medication is processed in your body.

The specific pharmacokinetics (how the drug is absorbed, distributed, metabolized, and eliminated) will vary from person to person.

What this means for your treatment:

It is important to follow your doctor’s instructions carefully when taking dichlorphenamide, including when to stop the medication if necessary. If you are considering stopping Keveyis or switching to a different medication, talk to your doctor about the appropriate timeline and any necessary monitoring or testing during the transition period.

Never skip doses or stop taking Keveyis without the supervision of your healthcare professional. If you need help affording your dichlorphenamide treatment, call QuickRx—we are always here to help with financial assistance programs.

QuickRx Specialty Pharmacy primarily dispenses generic dichlorphenamide unless your doctor specifically requires brand Keveyis or your insurance only covers the brand version. Here’s what you need to know about generic dichlorphenamide versus brand Keveyis:

Why we recommend generic dichlorphenamide:

Same active ingredient: Generic dichlorphenamide contains the exact same active pharmaceutical ingredient as brand Keveyis—dichlorphenamide—in the same strengths and dosage forms.

FDA-approved bioequivalence: The FDA requires generic medications to be bioequivalent to their brand-name counterparts, meaning generic dichlorphenamide works the same way in your body as Keveyis. It has the same absorption rate, the same effectiveness, and the same safety profile.

Lower cost: Generic dichlorphenamide typically costs significantly less than brand Keveyis, even before copay assistance programs are applied. This makes it more affordable for patients and can reduce insurance costs.

Same manufacturer standards: Generic dichlorphenamide must meet the same strict FDA manufacturing and quality standards as brand Keveyis. The facilities that produce generic medications are regularly inspected and must maintain the same quality controls.

Copay assistance for generic dichlorphenamide:

QuickRx helps patients access financial assistance for generic dichlorphenamide through manufacturer programs and patient assistance options.

When brand Keveyis might be required:

In certain situations, your doctor might specify “brand necessary” or “DAW” (dispense as written) for Keveyis. If your prescription specifies brand Keveyis, QuickRx will dispense exactly what your doctor prescribed and help you access copay assistance for the brand version.

Questions about generic dichlorphenamide versus brand Keveyis?

Call QuickRx at (917) 83-2525 or toll-free at (800) 496-6111 to discuss whether your prescription allows generic substitution and to get a cost comparison for your specific insurance.

Medical References

The medical information on this page is based on peer-reviewed clinical literature and authoritative drug references:

• Dichlorphenamide (Keveyis) prescribing information. Xeris Pharmaceuticals Inc; July 2025.
• Dichlorphenamide (Ormalvi) prescribing information. Cycle Pharmaceuticals; June 2025.
• Ciafaloni E, Cohen F, Griggs R. Efficacy and safety of dichlorphenamide for primary periodic paralysis in adolescents compared with adults. Pediatr Neurol. 2019;101:43-46.
• Sansone VA, Johnson NE, Hanna MG, et al. Long-term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis. Muscle Nerve. 2021;64(3):342-346.
• Charles G, Zheng C, Lehmann-Horn F, Jurkat-Rott K, Levitt J. Characterization of hyperkalemic periodic paralysis: a survey of genetically diagnosed individuals. J Neurol. 2013;260(10):2606-2613.
• Levitt JO. Practical aspects in the management of hypokalemic periodic paralysis. J Transl Med. 2008;6:18.

Important: This page provides educational information about Keveyis and dichlorphenamide copay assistance programs and is not intended as medical advice. All medical decisions should be made in consultation with your qualified healthcare provider.

Last reviewed: October 2025